This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martin-Oliva, D. Articles by Oliver, F. J. Search for Related Content PubMed PubMed Citation Articles by Martin-Oliva, D. Articles by Oliver, F. J.

Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis

¹ Institute of Parasitology and Biomedicine, Consejo Superior de Investigaciones Cientificas; ² Department of Cell Biology, Faculty of Sciences, ³ Department of Pathology, and ⁴ IBIMER, University of Granada, Granada, Spain; and ⁵ Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

Requests for reprints: F. Javier Oliver, Instituto de Parasitología y Biomedicina, Consejo Superior de Investigaciones Cientificas, Avda del Conocimiento s/n, 18100 Armilla, Granada, Spain. Phone: 34-958-181655; Fax: 34-958-181632; E-mail: joliver{at}ipb.csic.es.

Poly(ADP-ribose) polymerase (PARP)-1, an enzyme that catalyzes the attachment of ADP ribose to target proteins, acts as a component of enhancer/promoter regulatory complexes. In the present study, we show that pharmacologic inhibition of PARP-1 with 3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) results in a strong delay in tumor formation and in a dramatic reduction in tumor size and multiplicity during 7,12-dimethylbenz(a)anthracene plus 12-O-tetradecanoylphorbol-13-acetate–induced skin carcinogenesis. This observation was parallel with a reduction in the skin inflammatory infiltrate in DPQ-treated mice and tumor vasculogenesis. Inhibition of PARP also affected activator protein-1 (AP-1) activation but not nuclear factor-B (NF-B). Using cDNA expression array analysis, a substantial difference in key tumor-related gene expression was found between chemically induced mice treated or not with PARP inhibitor and also between wild-type and parp-1 knockout mice. Most important differences were found in gene expression for Nfkbiz, S100a9, Hif-1, and other genes involved in carcinogenesis and inflammation. These results were corroborated by real-time PCR. Moreover, the transcriptional activity of hypoxia-inducible factor-1 (HIF-1) was compromised by PARP inhibition or in PARP-1–deficient cells, as measured by gene reporter assays and the expression of key target genes for HIF-1. Tumor vasculature was also strongly inhibited in PARP-1–deficient mice and by DPQ. In summary, this study shows that inhibition of PARP on itself is able to control tumor growth, and PARP inhibition or genetic deletion of PARP-1 prevents from tumor promotion through their ability to cooperate with the activation AP-1, NF-B, and HIF-1. (Cancer Res 2006; 66(11): 5744-56)

This article has been cited by other articles:

				S Garcia, A Bodano, J L Pablos, J J Gomez-Reino, and C Conde Poly(ADP-ribose) polymerase inhibition reduces tumor necrosis factor-induced inflammatory response in rheumatoid synovial fibroblasts Ann Rheum Dis, May 1, 2008; 67(5): 631 - 637. [Abstract] [Full Text] [PDF]

				M. Elser, L. Borsig, P. O. Hassa, S. Erener, S. Messner, T. Valovka, S. Keller, M. Gassmann, and M. O. Hottiger Poly(ADP-Ribose) Polymerase 1 Promotes Tumor Cell Survival by Coactivating Hypoxia-Inducible Factor-1-Dependent Gene Expression Mol. Cancer Res., February 1, 2008; 6(2): 282 - 290. [Abstract] [Full Text] [PDF]

				K. Ratnam and J. A. Low Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology Clin. Cancer Res., March 1, 2007; 13(5): 1383 - 1388. [Abstract] [Full Text] [PDF]